Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC

GSE5851

Homo sapiens

80 Downloadable Samples

Affymetrix Human Genome U133A 2.0 Array (hgu133a2)

Submitter Supplied Information

Description

Patients with metastatic colorectal cancer were enrolled for treatment with cetuximab monotherapy. Transcriptional profiling was conducted on RNA from pre-treatment metastatic site biopsies to identify genes whose expression correlates with best clinical responses.

PubMed ID

17664471

Publication Title

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Total Samples

Submitter’s Institution

Bristol-Myers Squibb Pharmaceutical Research Institute

Authors

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ

Source Repository

Gene Expression Omnibus (GEO)

Alternate Accession IDs

E-GEOD-5851

No rows found